LEAP-012: transarterial chemoembolisation with lenvatinib plus pembrolizumab versus placebo for unresectable non-metastatic hepatocellular carcinoma
Adding lenvatinib and pembrolizumab to chemoembolisation delayed progression in intermediate-stage liver cancer, the second trial to show that systemic therapy improves on embolisation alone, at the cost of more side effects.
Overview
Phase 3 placebo-controlled trial of 480 patients with unresectable, non-metastatic hepatocellular carcinoma suitable for chemoembolisation randomised to transarterial chemoembolisation with lenvatinib plus pembrolizumab or with dual placebo.
Median progression-free survival was 14.6 versus 10.0 months (hazard ratio 0.66), with an early trend in overall survival (hazard ratio 0.80, not significant) and grade 3 to 4 treatment-related adverse events of 71 versus 32 percent.
- Median progression-free survival 14.6 vs 10.0 months; hazard ratio 0.66.
- Grade 3 to 4 treatment-related adverse events 71 percent vs 32 percent.
Lenvatinib-pembrolizumab with chemoembolisation is an emerging option for intermediate-stage disease, balanced against substantial toxicity.
- Overall survival not yet significant.
- High toxicity may limit uptake.
Similar pages
not linked directly; found by shared links- Key paperArterial embolisation or chemoembolisation versus symptomatic treatment in unresectable hepatocellular carcinoma
Shares Intermediate hepatocellular carcinoma (BCLC B), The Lancet.
- TrialLEAP-002
Shares Lenvatinib, Pembrolizumab.
- TrialA Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepat
Shares Intermediate hepatocellular carcinoma (BCLC B), Lenvatinib.
- Key paperEMERALD-1: durvalumab with or without bevacizumab added to transarterial chemoembolisation for embolisation-eligible hepatocellular carcinoma
Shares Intermediate hepatocellular carcinoma (BCLC B), The Lancet.
- PairingTACE + immunotherapy/anti-VEGF
Shares LEAP-012, Intermediate hepatocellular carcinoma (BCLC B).
- TrialPembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surge
Shares Lenvatinib, Pembrolizumab.
- TrialLITESPARK-012
Shares Lenvatinib, Pembrolizumab.
- Key paperREFLECT: lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma
Shares The Lancet, Lenvatinib.